Three US studies estimated that semaglutide was cost-effective versus standard care for adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and stage F2 or F3 fibrosis. Their estimates were $19,911, $42,200 and $80,076 per quality-adjusted life year (QALY) gained in the scenarios shown here [1] [2] [3]. Each fell below the study’s chosen threshold.
Wegovy injection has FDA accelerated approval for this indication [5]. The liver trials provide the clinical context for those projections, while economic studies of weight-loss treatment address a different population. One QALY represents one year of life in full health.
Three models, three figures
The lowest ratio comes from a lifetime model taken from the perspective of a US third-party payer. The model projected 1.66 additional QALYs with semaglutide at an incremental cost of $33,031, for a ratio of $19,911 per QALY, and it was cost effective in 99.5% of simulations at a $150,000 threshold [1]. Two of its three authors are employees and shareholders of Novo Nordisk, which makes semaglutide, and the third works for a firm Novo Nordisk contracted to develop the model and write the manuscript.
An academic model from a Yale-based group ran shorter horizons for patients with F2 to F3 fibrosis and found semaglutide cost-effective at $42,200 per QALY over five years and $44,138 over ten [2]. When the model added semaglutide’s cardiovascular mortality benefit, the ratio improved to $38,324, and the authors declared no competing interests.
A third model, from Georgia Tech and Cleveland Clinic, used a lifetime horizon and a $100,000 threshold [3]. Semaglutide came in at $80,076 per QALY with an 89.8% probability of being cost-effective under the modeled assumptions. Tirzepatide came in at $42,705 per QALY. Its effect estimate came from an indirect comparison that used phase 2 data. Drug price had the largest influence in this model’s sensitivity analyses.
What the cash price does to the answer
McGovern and colleagues modeled a $499-per-month cash price for semaglutide 2.4 mg. At that assumed price, the model projected lower total costs and more QALYs than standard care [1]. The study used $499 as a scenario input. Current GLP-1 cash prices depend on the specific product, dose and payment terms.
Semaglutide against resmetirom
McGovern’s model put resmetirom at $346,810 per QALY for 80 mg and $198,607 for 100 mg [1], and the Cleveland Clinic model at $273,445, above its threshold [3]. The Yale model put it at $95,981 over five years, below a $150,000 threshold [2].
Value and effect are different rankings. The same Yale model projected that treating 100,000 patients over ten years would prevent 1,040 liver-related deaths with semaglutide and 1,180 with resmetirom [2]. Semaglutide ranked better on cost per QALY while resmetirom prevented more liver-related deaths in that projection.
Outside the US
A twelve-country economic model studied adults with type 2 diabetes. It estimated that screening followed by intensive lifestyle intervention plus semaglutide was cost-effective in eleven countries, with Tanzania the exception. The corresponding pathway with resmetirom met the threshold in eight [4]. Studies of liver screening in people with diabetes address the separate question of whom to test.
These estimates compare projected costs and health outcomes for populations. The result depends on the price, time horizon and assumptions each model uses.